← Back to Screener
AnaptysBio, Inc. Common Stock (ANAB)
Price$50.95
Favorite Metrics
Price vs S&P 500 (26W)106.46%
Price vs S&P 500 (4W)-1.24%
Market Capitalization$1.46B
All Metrics
P/CF (Annual)74.36x
Book Value / Share (Quarterly)$1.33
P/TBV (Annual)1.45x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)183.56%
Cash Flow / Share (Quarterly)$0.70
Price vs S&P 500 (YTD)35.12%
Net Profit Margin (TTM)-5.64%
EPS (TTM)$-0.32
10-Day Avg Trading Volume0.54M
EPS Excl Extra (TTM)$-0.32
Revenue Growth (5Y)25.62%
EPS (Annual)$-0.46
ROI (Annual)-4.22%
Net Profit Margin (5Y Avg)-492.16%
Cash / Share (Quarterly)$11.12
Revenue Growth QoQ (YoY)151.08%
ROA (Last FY)-3.63%
Revenue Growth TTM (YoY)157.01%
EBITD / Share (TTM)$-0.89
ROE (5Y Avg)-98.31%
Operating Margin (TTM)20.42%
Cash Flow / Share (Annual)$0.70
P/B Ratio39.36x
P/B Ratio (Quarterly)36.07x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)6.41x
Net Interest Coverage (TTM)-199.47x
ROA (TTM)-3.59%
EV / EBITDA (TTM)182.41x
EPS Incl Extra (Annual)$-0.46
Current Ratio (Annual)9.07x
Quick Ratio (Quarterly)8.94x
3-Month Avg Trading Volume0.53M
52-Week Price Return254.20%
EV / Free Cash Flow (Annual)76.65x
Revenue / Employee (TTM)$2
Tangible BV / Share (Quarterly)$4.53
P/S Ratio (Annual)6.24x
Asset Turnover (Annual)0.64x
52-Week High$73.30
Operating Margin (5Y Avg)-454.55%
EPS Excl Extra (Annual)$-0.46
CapEx CAGR (5Y)-31.34%
Tangible BV CAGR (5Y)-3.15%
26-Week Price Return115.21%
Quick Ratio (Annual)8.94x
13-Week Price Return34.32%
Total Debt / Equity (Annual)7.43x
Current Ratio (Quarterly)9.07x
Enterprise Value$1,503.056
Revenue / Share Growth (5Y)24.32%
Asset Turnover (TTM)0.64x
Book Value / Share Growth (5Y)-37.99%
Revenue / Employee (Annual)$2
Pretax Margin (Annual)-5.57%
Cash / Share (Annual)$11.12
3-Month Return Std Dev64.96%
Net Income / Employee (TTM)$-0
EBITDA Interim CAGR (5Y)7.21%
ROE (Last FY)-35.56%
Net Interest Coverage (Annual)-18.43x
EPS Basic Excl Extra (Annual)$-0.46
P/FCF (TTM)14.95x
Receivables Turnover (TTM)6.73x
EV / Free Cash Flow (TTM)76.65x
Total Debt / Equity (Quarterly)7.43x
EPS Incl Extra (TTM)$-0.32
Receivables Turnover (Annual)8.96x
ROI (TTM)3.03%
P/S Ratio (TTM)6.24x
Pretax Margin (5Y Avg)-492.11%
Revenue / Share (Annual)$8.16
Tangible BV / Share (Annual)$9.19
Price vs S&P 500 (52W)219.10%
Year-to-Date Return39.25%
5-Day Price Return-1.78%
EPS Normalized (Annual)$-0.46
ROA (5Y Avg)-19.98%
Net Profit Margin (Annual)-5.64%
Month-to-Date Return21.73%
Cash Flow / Share (TTM)$-5.37
EBITD / Share (Annual)$-0.90
Operating Margin (Annual)20.42%
LT Debt / Equity (Annual)7.43x
P/CF (TTM)74.36x
ROI (5Y Avg)-28.96%
LT Debt / Equity (Quarterly)7.43x
EPS Basic Excl Extra (TTM)$-0.32
P/TBV (Quarterly)3.15x
P/B Ratio (Annual)36.07x
Pretax Margin (TTM)-5.57%
Book Value / Share (Annual)$1.33
Price vs S&P 500 (13W)31.46%
Beta0.47x
P/FCF (Annual)74.69x
Revenue / Share (TTM)$8.45
ROE (TTM)28.88%
52-Week Low$17.11
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.21
4.26
4.26
4.26
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ANABAnaptysBio, Inc. Common Stock | 6.24x | 157.01% | — | — | $50.95 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
AnaptysBio Inc develops immune cell-modulating antibody therapies for inflammatory and autoimmune diseases. The company's lead program, rosnilimab, a PD-1 agonist, is in Phase 2b trials for rheumatoid arthritis and Phase 2 trials for ulcerative colitis. It is also developing ANB032, a BTLA agonist in Phase 2b testing for atopic dermatitis.